Non-atherosclerotic myocardial infarction in hypereosinophilic syndrome: emerging insights and therapeutic approaches Authors: Jiao Li, Wenjun Jia, Qi Li, Yue Liu, Zhenying Zhou, Liping Wei Published: 2026 ABSTRACT AbstractHypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in blood and tissues, with multisystem involvement. Cardiac manifestations are frequent in HES and significantly worsen prognosis. Recent evidence establishes a direct link between HES and myocardial infarction (MI), demonstrating that HES induces MI primarily via non-atherosclerotic mechanisms. Critically, HES-related MI is fundamentally distinct from atherosclerotic MI in pathogenesis, diagnosis and management. This paradigm shift redefines diagnostic frameworks for cardiovascular disease and provides targeted strategies for non-atherosclerotic MI. This review synthesises current knowledge on HES-associated MI, emphasising its unique epidemiology, pathophysiology, evidence-based diagnostic criteria and mechanism-specific therapies. Future research priorities are discussed to advance clinical translation. Introduction Hypereosinophilic syndrome (HES) encompasses a heterogeneous spectrum of diseases distinguished by the abnormal and sustained increase of eosinophils in blood and tissues, with the capacity to impact multiple organ systems.1 Its clinical manifestations are highly variable, ranging from mild cutaneous symptoms to severe and potentially life-threatening cardiovascular, haematological and neurological manifestations.2 The heart is among the target organs that are particularly vulnerable to involvement in HES. Roughly 13–22% of patients with HES experience cardiac complications, such as endomyocardial fibrosis, mural thrombus formation and myocarditis. In severe instances, it can progress to restrictive cardiomyopathy and myocardial infarction (MI).3 Traditionally, it has been believed that MI is predominantly induced by coronary atherosclerosis. Nevertheless, recent research has demonstrated that HES can precipitate MI through a variety of mechanisms, posing a grave threat to patients’ lives. Currently, there are still numerous gaps in our understanding of MI caused by HES. Current understanding of MI caused by HES remains substantially limited, lacking a comprehensive synthesis of the mechanisms underlying HES-triggered MI. This review integrates key recent findings to propose a unified ‘eosinophil-mediated cytotoxic cascade” model that elucidates the pathogenesis of HES-MI. It establishes evidence-based diagnostic criteria incorporating integrated haematological/cardiac biomarkers and evaluates a stratified therapeutic strategy centred on myocardial salvage. By bridging haematological and cardiological paradigms, this work aims to optimise clinical decision-making for this high-risk patient population. Epidemiology and classification of HES Epidemiological characteristics HES is a rare disorder with limited epidemiological data due to disease heterogeneity. Based on the SEER (Surveillance, Epidemiology, and End Results) database (2004–2015; International Classification of Diseases-O code 9964/3), the age-adjusted incidence is approximately 0.4 per million individuals.4 Cardiac involvement occurs in 5% of acute-stage and 20% of chronic-stage cases, representing a major cause of mortality.3 Notably, 5–10% of patients with HES develop MI, with some idiopathic cases diagnosed postinfarction.5 Definitions and classification The diagnostic criteria, first proposed by the “International Cooperative Working Group on Eosinophil Disorders” (ICOG-EO) in 2011 and later revised, mainly distinguish among blood eosinophilia (eosinophil count 0.5–1.5×10⁹/L), hypereosinophilia (blood eosinophil count >1.5×10⁹/L and/or tissue eosinophilia) and HES. Specifically, HES diagnosis requires: an absolute eosinophil count (AEC) in peripheral blood of ≥1.5×10⁹/L, confirmed by two tests at least 2 weeks apart; eosinophil-mediated organ damage or dysfunction; and exclusion of other causes, such as parasitic infections and allergic disorders.6 HES is classified as7: idiopathic (includes lymphocytic variant); primary (clonal disorders, eg, FIP1L1-platelet-derived growth factor receptor α (PDGFRA)+CEL); secondary (triggered by allergies, infections, autoimmune diseases or solid tumours via chemotactic factors); and familial (rare hereditary form linked to 5q31-33 encoding interleukin (IL)-3/IL-5/granulocyte-macrophage colony-stimulating factor (GM-CSF)). Pathogenesis The pathogenesis of HES is complex and incompletely understood. It is currently thought to be related to multiple factors. Genetic abnormalities In primary HES, clonal abnormalities of haematopoietic stem cells are crucial. Take the FIP1L1-PDGFRA fusion gene. It forms due to a cryptic chromosomal deletion, fusing the FIP1L1 and PDGFRA genes. This fusion gene constitutively activates PDGFRA, triggering downstream signalling pathways, such as JAK-STAT, PI3K-AKT and RAS-MAPK.8 Aberrant activation of these pathways drives uncontrolled eosinophil proliferation, differentiation and apoptosis inhibition, leading to eosinophil accumulation in blood and tissues. Mutations or dysregulated expressions of other genes may also contribute to HES pathogenesis, but the exact mechanisms need further studies. Immune regulatory dysfunctions The immune system is central to HES development.9 Some patients with HES have immune dysregulation, manifested as T-lymphocyte dysfunction. There is an imbalance in helper T-cell (Th) subsets, with Th2 cell over-activation leading to abundant IL secretion, such as IL-3, IL-5 and GM-CSF. These cytokines promote eosinophil growth, differentiation, survival and chemotaxis, causing their abnormal increase. Meanwhile, regulatory T-cell function may be impaired, failing to effectively suppress excessive immune responses and exacerbating eosinophil hyperactivity. Additionally, B-lymphocyte-derived autoantibodies may be involved. Immune complex formation and deposition activate the complement system, causing tissue damage and attracting eosinophil infiltration.10 11 Cytokine network imbalance Besides Th2-derived cytokines, others like tumour necrosis factor (TNF) and transforming growth factor-beta (TGF-β) play important roles in HES pathogenesis.12 TNF enhances eosinophil activation and adhesion, facilitating tissue migration. TGF-β is involved in eosinophil-mediated tissue fibrosis by promoting fibroblast proliferation and extracellular matrix synthesis, aggravating organ damage. Cytokines interact to form a complex network; disruption of any component can trigger HES onset and progression. External stimuli In secondary HES, external stimuli are key inducers. During parasitic infections, parasite-released antigens activate the immune system, eliciting a Th2-type response and eosinophil increase for defence. Allergic reactions are common triggers. Exposure to allergens prompts immunoglobulin E (IgE) production. IgE binds to mast cell and basophil receptors, sensitising these cells. Re-exposure to the allergen releases bioactive molecules like histamine and leukotrienes, attracting and activating eosinophils. In autoimmune diseases, immune system derangement generates self-reactive antibodies, triggering inflammation and a reactive eosinophilia.13 Cardiac involvement HES exerts a profound influence on patient prognosis. A subset of patients succumbs to complications like congestive heart failure and endomyocardial lesions.14 Cardiac involvement presents with diverse clinical manifestations, typically encompassing mural thrombus formation at the apices of the left and right ventricles, endocardial thickening, left ventricular dilation and mitral regurgitation attributable to the involvement of the mitral valve’s posterior leaflet. Research indicates that approximately one-third of patients with primary HES are predisposed to endomyocardial fibrosis, whereas the likelihood of cardiac involvement in patients with secondary HES is comparatively low.15 Pathologically, cardiac involvement in HES unfolds in three stages.16 During the acute necrosis stage, eosinophils infiltrate the myocardium and secrete toxic granule proteins, culminating in myocardial cell necrosis. In the thrombus-formation stage, endocardial injury precipitates mural thrombus development, augmenting the embolism risk. The fibrosis stage is characterised by persistent eosinophilic inflammation, giving rise to subendocardial fibrosis that may progress to restrictive or dilated cardiomyopathy. This process can also impact heart valves, causing diminished valve mobility and valvular insufficiency. Notably, the progression of cardiac disease in HES is unpredictable, with potential overlap among the stages. Furthermore, no clear association exists between the incidence and severity of cardiac involvement and systemic symptoms or involvement of other organs.17 Pathophysiological mechanisms underlying myocardial infarction induced by HES Direct myocardial injury Cytotoxicity of eosinophil granule proteins The toxic impact of eosinophils on the vascular wall, be it arterial or venous, represents a pathological outcome of eosinophil accumulation. Activated eosinophils are replete with diverse toxic granule proteins. Among these, major basic protein (MBP) and eosinophil peroxidase (EPO) stand as pivotal effector molecules in mediating myocardial injury.18 MBP, due to its highly cationic nature, binds to the negatively charged myocardial cell membrane. This binding disrupts membrane integrity, ultimately culminating in apoptosis. Conversely, EPO catalyses the production of a substantial quantity of reactive oxygen species, thereby inducing mitochondrial dysfunction.19 Remodelling of the myocardial microenvironment Eosinophil infiltration has the capacity to modify the myocardial microenvironment and drive the fibrotic process.20 Eosinophils activate cardiac fibroblasts through the release of TGF-β and matrix metalloproteinases. This activation leads to the overdeposition of extracellular matrix. T1 mapping using cardiac magnetic resonance (CMR) reveals a significant increase in the extracellular volume of myocardial cells in patients with HES, indicating early-stage fibrotic alterations.21 Coronary artery lesions Coronary vasculitis Infiltration of eosinophils into the coronary artery wall can instigate vasculitis,22 leading to thickening of the vessel wall and stenosis of the lumen. Pathologically, it is characterised by: (1) Inflammatory cell infiltration, predominantly eosinophils, throughout the entire vessel wall; (2) Intimal hyperplasia accompanied by fibrinoid necrosis; (3) Adventitial fibrosis. Accordingly, intravascular ultrasound examination in patients with HES with concomitant MI may disclose a reduction in the area of the external elastic membrane of HES vessels (negative remodelling), distinct from the positive remodelling observed in atherosclerosis. Coronary artery spasm Coronary artery spasm represents a prevalent cause of myocardial ischaemia in patients with non-obstructive coronary artery disease (CAD). However, in 10–20% of cases, patients with coronary artery spasm are unresponsive to both calcium channel blockers and nitrate therapies.23 Among these patients, some exhibit concomitant peripheral blood eosinophilia or suffer from eosinophilia-associated disorders,24 25 such as aspirin-exacerbated respiratory disease, eosinophilic granulomatosis with polyangiitis (EGPA) and eosinophilic oesophagitis. Eosinophilia-related coronary vasospasm remains a poorly characterised condition. Its clinical manifestations resemble those of typical coronary artery spasm, yet the underlying mechanisms and treatment modalities differ.26 Classical coronary artery spasm is mediated by hyperactivity of vascular smooth muscle cells and decreased endogenous nitric oxide production in coronary artery endothelial cells. Conversely, in patients with eosinophilia, spasm is attributed to the infiltration of eosinophils and mast cells into the adventitia of the coronary artery. Vasoactive substances, including histamine and leukotrienes, released by eosinophils can trigger coronary artery spasm. Kounis syndrome, an allergic-related acute coronary syndrome, is characterised by myocardial ischaemia or infarction induced by coronary artery spasm, with no notable stenosis detected by coronary angiography. It accounts for 15–20% of HES-related MI cases.27 This prompts clinicians to conduct a differential cell count in patients initially diagnosed with variant angina. When the AEC is markedly elevated, long-term use of glucocorticoids or anti-IL-5 biologics is warranted to reduce eosinophil numbers.24 Additionally, Thomas et al28reported a case where a patient developed in-stent thrombosis, eosinophilia and rash following the implantation of durable polymer-coated drug-eluting stents (DP-DES). These manifestations are consistent with allergic MI, a form of Kounis syndrome. The patient’s condition was triggered by a metal allergy to DP-DES and necessitated long-term immunosuppressive treatment. Thrombosis and embolism Elevated eosinophils in the blood of patients with HES can activate the coagulation system, facilitate platelet aggregation and adhesion, and thereby augment the risk of thrombosis.29 Endocardial injury and mural thrombus formation are characteristic manifestations of cardiac involvement in HES. Once detached, the thrombus may cause coronary artery embolism, precipitating acute MI (AMI). Clinical observations indicate that approximately 30% of patients with HES with cardiac lesions have intracardiac thrombi, signifying that thromboembolism is a crucial mechanism underlying MI.30 31 Clinical diagnosis, treatment strategies and challenges of HES complicated with MI Diagnostic difficulties The clinical presentations of HES complicated by MI closely resemble those of coronary atherosclerotic MI, thereby predisposing to misdiagnosis. Some patients present with atypical symptoms, such as abdominal pain and headache, further compounding the diagnostic challenge. Diagnosis hinges on multiple examinations, encompassing complete blood count, bone marrow aspiration, genetic testing (eg, for the FIP1L1-PDGFRA fusion gene), CMR and endomyocardial biopsy.32 33 In practical diagnosis, complete blood count is typically the initial step to preliminarily assess eosinophil levels. Detection of an abnormal elevation prompts consideration of subsequent, more intricate examinations. Bone marrow aspiration facilitates understanding of haematopoietic cell status. Genetic testing is pivotal for identifying specific gene mutations in primary HES, while CMR and endomyocardial biopsy directly evaluate myocardial structural and functional alterations. Arun et al reported a case of a patient with AMI. Cardiac catheterisation yielded negative results, yet cardiac MRI revealed subendocardial hypoperfusion attributable to ischaemia/infarction, and the patient experienced cerebral infarction in diverse vascular regions. After comprehensive evaluation, vasculitis was suspected, and ultimately, a diagnosis of HES was established.34 Furthermore, MI induced by HES must be differentiated from a plethora of other conditions, including atherosclerotic acute coronary syndrome, myocarditis (notably eosinophilic myocarditis), stress-induced cardiomyopathy and systemic vasculitis (eg, EGPA). The diagnostic approach for HES-associated MI should adhere to the diagnostic pathway for MI with non-obstructive coronary arteries, and a multimodal diagnostic strategy is advocated.35 36 As summarised in table 1, fundamental differences exist between HES-induced MI and atherosclerotic AMI in pathogenesis, diagnosis and treatment strategies, highlighting the need to avoid misapplication of conventional CAD management protocols in clinical practice. For instance, patients presenting with chest pain and elevated AEC require urgent exclusion of coronary obstruction. If coronary arteries are normal, HES-MI diagnosis should be confirmed through either the triple CMR features (oedema, late gadolinium enhancement and microvascular obstruction) or endomyocardial biopsy, followed by immediate initiation of antieosinophil therapy (figure 1). Diagnostic flowchart. CAD, coronary artery disease; CAG, coronary angiography; HES, hypereosinophilic syndrome; LGE, late gadolinium enhancement; MI, myocardial infarction; PDGFRA, platelet-derived growth factor receptor α. Table 1Key differences between HES-MI and atherosclerotic MIHES-induced MIAtherosclerotic MIPathogenesis Eosinophil infiltration and release of toxic granule proteins.Coronary microvascular spasm/endothelial dysfunction.Endocardial microthrombus formation.Myocardial inflammatory necrosis (non-coronary obstructive). Atherosclerotic plaque rupture/erosion.Secondary platelet aggregation and thrombus formation.Myocardial ischaemia due to occlusion of large/medium coronary vessels. Imaging features CMR: subendocardial LGE, myocardial oedema.Echocardiography: endocardial thickening, mural thrombus, ventricular diastolic dysfunction.Coronary CTA: microvascular disease (absence of large vessel obstruction). CAG: large vessel stenosis/occlusion.CMR: transmural/epicardial LGE (corresponding to coronary distribution).Echocardiography: regional wall motion abnormalities. Core biomarkers AEC (>1.5×10⁹/L).Myocardial injury markers: cTnI/T (persistent moderate elevation). Myocardial necrosis markers: cTnI/T (dynamic steep rise and fall).Thrombosis/ischaemia markers: CK-MB, myoglobin. Treatment Targeted therapy prioritised: Corticosteroids (rapid eosinophil reduction).Biologics (anti-IL-5/IL-5Rα).Anticoagulation (to prevent microthrombi).Conventional antiplatelet therapy ineffective. Revascularisation as the core strategy: Emergency PCI/CABG.Intensive antiplatelet therapy (Aspirin+P2Y12 inhibitor).Statin lipid-lowering therapy.Corticosteroids ineffective/harmful. Prognostic features Survival dependent on HES control High early recurrence rate (if eosinophils uncontrolled).Heart failure as the primary cause of death. Survival dependent on CAD management Reinfarction associated with atherosclerosis progression.High risk of sudden cardiac death/arrhythmias. AEC, absolute eosinophil count; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAG, coronary angiography; CK-MB, creatine kinase-myocardial band; CMR, cardiac MRI; CTA, CT angiography; cTnI/T, cardiac troponin I or T; HES, hypereosinophilic syndrome; IL, interleukin; LGE, late gadolinium enhancement; MI, myocardial infarction; PCI, percutaneous coronary intervention. Key differences between HES-MI and atherosclerotic MI Eosinophil infiltration and release of toxic granule proteins. Eosinophil infiltration and release of toxic granule proteins. Coronary microvascular spasm/endothelial dysfunction. Coronary microvascular spasm/endothelial dysfunction. Endocardial microthrombus formation. Endocardial microthrombus formation. Myocardial inflammatory necrosis (non-coronary obstructive). Myocardial inflammatory necrosis (non-coronary obstructive). Atherosclerotic plaque rupture/erosion. Atherosclerotic plaque rupture/erosion. Secondary platelet aggregation and thrombus formation. Secondary platelet aggregation and thrombus formation. Myocardial ischaemia due to occlusion of large/medium coronary vessels. Myocardial ischaemia due to occlusion of large/medium coronary vessels. CMR: subendocardial LGE, myocardial oedema. CMR: subendocardial LGE, myocardial oedema. Echocardiography: endocardial thickening, mural thrombus, ventricular diastolic dysfunction. Echocardiography: endocardial thickening, mural thrombus, ventricular diastolic dysfunction. Coronary CTA: microvascular disease (absence of large vessel obstruction). Coronary CTA: microvascular disease (absence of large vessel obstruction). CAG: large vessel stenosis/occlusion. CAG: large vessel stenosis/occlusion. CMR: transmural/epicardial LGE (corresponding to coronary distribution). CMR: transmural/epicardial LGE (corresponding to coronary distribution). Echocardiography: regional wall motion abnormalities. Echocardiography: regional wall motion abnormalities. AEC (>1.5×10⁹/L). AEC (>1.5×10⁹/L). Myocardial injury markers: cTnI/T (persistent moderate elevation). Myocardial injury markers: cTnI/T (persistent moderate elevation). Myocardial necrosis markers: cTnI/T (dynamic steep rise and fall). Myocardial necrosis markers: cTnI/T (dynamic steep rise and fall). Thrombosis/ischaemia markers: CK-MB, myoglobin. Thrombosis/ischaemia markers: CK-MB, myoglobin. Corticosteroids (rapid eosinophil reduction). Corticosteroids (rapid eosinophil reduction). Biologics (anti-IL-5/IL-5Rα). Biologics (anti-IL-5/IL-5Rα). Anticoagulation (to prevent microthrombi). Anticoagulation (to prevent microthrombi). Conventional antiplatelet therapy ineffective. Conventional antiplatelet therapy ineffective. Emergency PCI/CABG. Emergency PCI/CABG. Intensive antiplatelet therapy (Aspirin+P2Y12 inhibitor). Intensive antiplatelet therapy (Aspirin+P2Y12 inhibitor). Statin lipid-lowering therapy. Statin lipid-lowering therapy. Corticosteroids ineffective/harmful. Corticosteroids ineffective/harmful. High early recurrence rate (if eosinophils uncontrolled). High early recurrence rate (if eosinophils uncontrolled). Heart failure as the primary cause of death. Heart failure as the primary cause of death. Reinfarction associated with atherosclerosis progression. Reinfarction associated with atherosclerosis progression. High risk of sudden cardiac death/arrhythmias. High risk of sudden cardiac death/arrhythmias. AEC, absolute eosinophil count; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAG, coronary angiography; CK-MB, creatine kinase-myocardial band; CMR, cardiac MRI; CTA, CT angiography; cTnI/T, cardiac troponin I or T; HES, hypereosinophilic syndrome; IL, interleukin; LGE, late gadolinium enhancement; MI, myocardial infarction; PCI, percutaneous coronary intervention. The dilemma between eosinophil control and antithrombotic therapy The primary objective of HES treatment is to mitigate eosinophil-mediated organ damage. Currently, glucocorticoids remain the first-line therapeutic agents.37 Their underlying mechanisms involve inhibiting the generation of new eosinophils, inducing eosinophil apoptosis or sequestration.38 However, these drugs may heighten the bleeding risk associated with antithrombotic therapy. Glucocorticoids can impede platelet function and prolong bleeding time. When combined with antiplatelet agents (such as aspirin and clopidogrel), the bleeding risk escalates further. In clinical practice, physicians must meticulously balance the intensity of antithrombotic therapy and the HES management plan according to patients’ specific circumstances, such as the outcomes of thrombosis and bleeding risk assessment scales. When necessary, regularly monitor coagulation function parameters, including platelet count, prothrombin time and activated partial thromboplastin time, and adjust drug dosages promptly. The complexity of multisystem involvement HES frequently affects multiple systems. Besides the heart, it can impact the skin, nervous system, digestive system, etc. During the treatment process, it is essential to comprehensively consider the pathological conditions of each system and formulate an individualised treatment plan. For instance, in patients with concomitant peptic ulcers, the use of glucocorticoids may exacerbate the ulcers, potentially leading to gastrointestinal bleeding. In such cases, physicians may need to implement gastric mucosa-protecting measures, such as using proton pump inhibitors or gastric mucosal protectants while treating HES. In patients with concomitant nervous system lesions, the neurotoxicity of certain drugs may further compromise nerve function. Additionally, several studies have indicated that elevated eosinophils may cause stenosis of intracranial arteries, augmenting the risk of ischaemic stroke.39 Hence, when formulating a treatment plan, it is imperative to fully account for organ involvement and drug interactions. Multidisciplinary consultations can be conducted to comprehensively consider the perspectives of various specialties and provide patients with the most suitable treatment. Disease recurrence and poor prognosis HES is a chronic disorder with a high recurrence propensity. Even when eosinophil levels are transiently controlled, the risk of cardiac reinvolvement persists. A retrospective study of 57 HES cases reported that the median survival time of patients was 9 months, and the 3-year survival rate was merely 12%.40 Such patients are often diagnosed at a relatively advanced disease stage. Autopsy findings indicate that congestive heart failure accounts for 65% of the causes of death. Besides heart disease, an increase in peripheral blood blasts or a white blood cell count exceeding 100×10⁹/L is an indicator of a poor prognosis. Clinical implications and future directions Expanding the diagnostic horizon For patients with MI, particularly those without significant stenosis revealed by coronary angiography or presenting with multisystem manifestations (eg, rash, fever, cough), peripheral blood eosinophil count and morphological examination should be conducted to exclude HES. Further diagnostic workup necessitates a combination of bone marrow aspiration, FIP1L1-PDGFRA fusion gene testing and CMR. Among these, CMR is invaluable in evaluating myocardial inflammation and fibrosis. Additionally, detailed inquiries regarding the patient’s allergy history and exposure to parasites (such as travel-related exposure) can aid in elucidating the aetiology of secondary HES. Multidisciplinary team approach HES complicated by MI, a condition with multi-system damage, urgently requires an MDT. The team usually includes cardiologists, adept at handling cardiac symptoms and MI outcomes in HES. Haematologists are crucial for discerning HES types using bone marrow and genetic data. Radiologists interpret imaging like CMR to reveal myocardial details. Rheumatologists join when autoimmune-related HES is suspected. Implementation of novel targeted therapies Tyrosine kinase inhibitors (eg, imatinib)41 exhibit over 90% efficacy in patients positive for FIP1L1-PDGFRA. Moreover, several investigations suggest that additional treatment modalities for HES are under investigation. In the therapeutic domain of HES, beyond the established cornerstone therapies of anti-IL-5/IL-5Rα monoclonal antibodies42 (eg, mepolizumab, benralizumab and GSK3511294 (benralizumab biosimilar) that effectively reduce eosinophil burden and clinical events, emerging targets and their corresponding interventional strategies are being actively explored. At the cytokine level, IL-4, IL-13 and their downstream STAT6 signalling pathway drive Th2-mediated inflammation, fibrosis and vascular dysfunction; the IL-4Rα-targeting monoclonal antibody dupilumab has demonstrated efficacy in other eosinophil-associated disorders, warranting evaluation of its potential value in HES-related cardiac complications. Chemokines such as CCL17 (thymus and activation regulated chemokine) and CCL26 (Eotaxin-3), along with their receptors (CCR3, CCR4), mediate eosinophil recruitment to cardiac tissue, thus representing emerging targets for tissue infiltration blockade.43 Cytotoxic granule proteins, including ECP and MBP, directly damage cardiomyocytes and endothelial cells and promote thrombosis; emerging research focuses on developing neutralising antibodies or small-molecule inhibitors to block these proteins’ cytotoxic effects or to interfere with their interactions with cell surface receptors such as protease-activated receptors, aiming to mitigate tissue damage.44 The anti-CD52 monoclonal antibody (alemtuzumab)45 and Siglec-8-targeting antibodies (lirentelimab)46 are currently in preclinical or early clinical research. Within key signalling pathways, the JAK-STAT pathway (particularly JAK1/JAK2-STAT5) serves as the core downstream pathway for multiple proeosinophilic cytokines, and JAK inhibitors47 (eg, ruxolitinib, baricitinib) have shown efficacy in specific HES subtypes (eg, lymphocytic variant) and in patients with myocarditis/fibrosis; concurrently, the PI3Kδ pathway plays a significant role in eosinophil function, and its inhibitors (eg, duselizumab, linperlisib) are under clinical development.48 Lastly, regarding fibrosis, TGF-β and galectin-3 are key mediators of eosinophil-associated myocardial fibrosis and remodelling; developing antifibrotic therapies targeting these molecules represents a crucial future direction for preventing long-term cardiac dysfunction in patients with HES.49 This article comprehensively summarises the main therapeutic strategies in table 2. Table 2HES treatment options summaryTreatment categoryRepresentative drugsMechanism of actionKey indicationsMajor limitationsCorticosteroidsPrednisone, MethylprednisoloneInhibit eosinophil differentiation/migration; reduce inflammationFirst-line for HES with multiorgan involvement; lymphocytic variant HES.Long-term toxicity (osteoporosis, diabetes); dependency/resistanceTKI PDGFRA/B fusion-positiveImatinibTarget aberrant PDGFRA/B kinase signallingPDGFRA/B-rearranged MLN-eo-TK.T674I mutation resistance; cardiotoxicity risk FGFR1 rearrangementPemigatinibInhibit FGFR1 fusion proteinRelapsed/refractory FGFR1-rearranged MLN-eo-TKrequires bridging to HSCT; poor blast-phase efficacy JAK2 fusionRuxolitinibBlock JAK-STAT pathwayJAK2-fusion MLN-eo-TKShort remission; mandates early HSCTBiological agents Anti-IL-5/IL-5RMepolizumabReduce eosinophil productionFDA-approved: steroid-sparing maintenance (idiopathic HES); PDGFRA-negative HESIneffective in myeloproliferative HES; short remission in lymphocytic HES Anti-CD52AlemtuzumabDeplete CD52+lymphocytes/eosinophilsRefractory lymphocytic variant HESSevere immunosuppression/infection risk Anti-IL-4RαDupilumabBlock IL-4/IL-13 signallingHES with comorbid eosinophilic oesophagitis or atopic dermatitisMay cause transient eosinophiliaCytotoxic agents HydroxyureaHydroxyureaInhibits DNA synthesis, reducing blood cell productionSteroid-refractory/dependent HESMyelosuppression; no long-term survival benefit Interferon-αIFN-α/PEG-IFN-αImmunomodulation; inhibits eosinophil proliferationSecond-line for steroid-refractory/intolerant HESFlu-like symptoms, depression; complex dose adjustmentHSCTAllo-HSCTRebuild non-clonal haematopoietic systemBlast-phase HES; TKI/biological-refractory HES with high-risk mutationsHigh transplant-related mortalitySource: Shomali & Gotlib, Am J Hematol 2024.37FDA, Food and Drug Administration; HES, hypereosinophilic syndrome; HSCT, haematopoietic stem cell transplantation; IFN, interferon; IL, interleukin; PDGFRA, platelet-derived growth factor receptor α; TKI, tyrosine kinase inhibitors. HES treatment options summary Source: Shomali & Gotlib, Am J Hematol 2024.37 FDA, Food and Drug Administration; HES, hypereosinophilic syndrome; HSCT, haematopoietic stem cell transplantation; IFN, interferon; IL, interleukin; PDGFRA, platelet-derived growth factor receptor α; TKI, tyrosine kinase inhibitors. Intensive monitoring and long-term follow-up Patients with HES complicated by MI require vigilant monitoring of disease progression. This includes routine assessment of complete blood count, myocardial enzyme profiles, ECGs, echocardiograms and other relevant indices to promptly detect disease recurrence and advancement. Postdischarge, long-term follow-up and regular reevaluations are essential. Concurrently, patients should be counselled on lifestyle modifications and empowered to enhance self-management, thereby minimising the risk of disease recurrence and cardiovascular events. In clinical practice, long-term follow-up of such patients facilitates timely recognition of disease changes, adjustment of treatment strategies and improvement of long-term prognosis. Conclusion As a crucial non-traditional cause of MI, HES is intricately linked to MI. HES can instigate MI through diverse mechanisms, gravely imperilling patients’ health. Clinicians should heighten their awareness of the multiple diagnostic possibilities associated with eosinophilia. When eosinophilia results in end-organ damage, the likelihood of HES must be comprehensively evaluated. Although some progress has been made in understanding the pathogenesis, diagnosis and treatment of HES complicated by MI, numerous challenges persist. These include incomplete knowledge of the pathogenesis, diagnostic difficulties and the arduous task of selecting and balancing treatment options. In the future, it is imperative to conduct further basic and clinical research, delve deeply into the molecular mechanisms underlying MI induced by HES, develop more sensitive and specific diagnostic tools and optimise treatment strategies to elevate the diagnostic and therapeutic standards for HES-associated MI. Simultaneously, strengthening multidisciplinary collaboration and enhancing clinicians’ familiarity with this condition are essential to achieve early diagnosis, standardised treatment and ultimately improve patients’ prognosis and quality of life.